Enforcement Report - Week of February 22, 2023
Liège, Belgium – 8 October 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it has acquired the global rights from the Baker Heart and Diabetes Institute (“the Baker Institute”
US FDA Enforcement Report- 8/June/2016
Walgreens Infusion Services, Ongoing Class II recall of Milrinone various strengths in dextrose because of Lack of sterility assurance.